Drug Profile
Research programme: rare disease therapeutics - Recursion Pharmaceuticals/Takeda
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Recursion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Unspecified in USA
- 09 Jan 2019 Takeda in-licenses drug candidates from Recursion Pharmaceuticals
- 10 Oct 2017 Recursion Pharmaceuticals signs a research collaboration agreement with Takeda for the development of therapeutics for rare diseases